SUPPLEMENTARY METHODS
50494, MP Biomedicals, Solon, Ohio). Additional patient samples were collected on local institutional IRB-approved biobanking protocols by collaborators.
RNA isolation
RNA was isolated from cell lines and healthy donor PBMCs using the NucleoSpin RNA Plus Kit (Cat# 740984.50, Macherey-Nagel, Germany) and from patient PBMCs or bone marrow using the AllPrep DNA/RNA Mini Kit (Cat# 80204, Qiagen, Germany). RNA was quantitated using the NanoDrop Lite Spectrophotometer (Nano Drop Technologies, Wilmington, DE).
Primer design
Targeted amplicon primers were designed for the AML MRD target genes and fusion genes of interest ( Supplementary Table 1 ) for use with the QIAseq Targeted RNA Panel system (Cat#333025, Qiagen, Germany). For each target, a BC and LA primer were designed to capture approximately 150-bp of the target sequence. The BC primer was designed as follows and targets the RNA sequence: 5'-RS2 sequence (AATGTACAGTATTGCGTTTTG) -UMI (12 random nucleotides) -gene specific primer 1 (GSP1) -3'. The LA primer was designed as follows and targets the cDNA sequence: 5'-FS2 sequence (TTCTTAGCGTATTGGAGTCC) -gene specific primer 2 (GSP2)-3'. GSP1 and GSP2 primer sequences were designed using Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) with considerations to minimize offtarget amplification, primer-dimer formation, overlap with known SNPs, and efficient mapping of the 150-bp sequencing read using the analysis pipeline outlined below.
Where possible, the GSP1 and GSP2 primer sequences matched or overlapped with regions targeted by the standardized TaqMan-based real-time quantitative PCR assays developed by the 'Europe Against Cancer' (EAC)/European LeukemiaNet (ELN) program 6, 7 .
AML MRD targeted RNA-sequencing library preparation and sequencing
Targeted RNA-sequencing libraries were prepared using the QIAseq Targeted RNA Custom Panel kit (Cat#333025, Qiagen, Germany), with significant modifications. Briefly, 250ng of RNA was treated with ezDNase (Cat# 11766051, Invitrogen, Carlsbad, CA) for 2 minutes (min) at 37°C. UMI assignment and cDNA generation was performed using the SuperScript IV First Strand Synthesis System (Cat# 18091050, Invitrogen, Carlsbad, CA), where the DNase-treated RNA was pre-incubated with 100nM each of BC primer ( Supplementary Table 1 ) at 65°C for 5 minutes and cDNA was synthesized by the SuperScript IV Reverse Transcriptase at 55°C for 10 min. The reaction was inactivated at 80°C for 20 min and residual RNA was removed from by incubating with RNase H at 37°C for 20 min. To ensure complete removal of excess BC primers, the cDNA synthesis reaction was subjected to two rounds of purification with QIAseq beads at 1.3X volume and eluted in 10µL of nuclease-free water. The purified cDNA was then incubated with 100nM each of LA primer ( Supplementary Table 1 ), 600nM RS2 primer (5'-AATGTACAGTATTGCGTTTTG-3'), and 6U HotStarTaq DNA Polymerase as follows:
95°C for 15 min, and 8 cycles of 95°C for 15 seconds (sec) and 60°C for 5 min. The DNA was purified with one round of QIAseq beads at 1.6X volume and eluted in 25µL of nuclease-free water. Finally, the purified DNA was amplified with universal adapter primers for Illumina platforms (QIAseq Targeted RNA 96-Index I, Cat# 333117, Qiagen, Germany) and 12U HotStarTaq DNA Polymerase at the following conditions: 95°C for 15 min, and 26 cycles of 95°C for 15 sec and 60°C for 2 min. The resulting library was purified with one round of QIAseq beads at 1.1X volume and eluted in 25µL of nuclease-free water. The final library was quantitated using the Qubit dsDNA HS Assay kit (Cat# Q32851, Invitrogen, Carlsbad, CA).
Single-end 150bp sequencing was performed on the Illumina MiSeq (v3 reagents) or
HiSeq 2500 (rapid run mode) using the QIAseq Read 1 Primer 1 custom primer (Qiagen, Germany) and following the manufacturer's protocol (Illumina, San Diego, CA).
Raw sequencing FASTQ files have been deposited in the NCBI Sequencing Read
Archive (SRA) database under accession PRJNA421563.
Bioinformatics pipeline
Raw sequencing FASTQ files were processed using cutadapt (version 1.14) 8 to remove the 5' and 3' adapter sequences and a custom Python script to remove the 12-mer UMI sequence from the beginning of each read and append the UMI sequence to the read name in the FASTQ file. Subsequently, the trimmed reads were aligned to the human reference genome (GRCh38) using the splice read aligner STAR (version 2.5.2b) 9 . The uniquely aligned and chimeric BAM files were used in the downstream analysis.
SAMtools (version 1.3.1) 10 was utilized to cluster the reads per amplicon per library. The intended primer locations were used as target coordinates. Off-target reads were not considered.
UMI cutoffs were determined for each library based on ABL1 counts to remove errors which may have arisen during library preparation/sequencing and to minimize background noise. First, the number of times each ABL1 unique UMI was repeated (n) per library was counted. Then, unique UMIs with counts greater than ω = µ(n) + 2σ(n), where µ is mean and σ is standard deviation, were removed. Next, the total number of times a unique UMI with (n) count was observed (m) was plotted on a graph, where (n) was plotted on x-axis and log10(m) was plotted on y-axis. The inflection point (i) (i.e., flattening of the graph curve) of the graph was calculated with (n) in the x-axis and log10(m) on the y-axis. We considered such an inflection point (i) as the UMI cutoff and only counted unique UMIs with (n) greater than (i) per amplicon. See Supplementary   Figure 2 for an example.
The full bioinformatics pipeline is available for download at: www.github.com/NHLBI-BCB/QMRD.
Target panel coverage analysis using TCGA AML dataset
To determine the fraction of patients covered by the targeted RNA-seq panel, patient data from The Cancer Genome Atlas (TCGA) AML cohort 11 was analyzed. Only patients for which there was clinical data, mutation analysis, and RNA-seq were included in the analysis (n=173). Across the 173 patients, the proportion of patients with NPM1 exon 12 insertion mutations, PML-RARA, RUNX1-RUNX1T1, CBFB-MYH11, and BCR-ABL1 fusions were calculated. Utilizing the RNA-seq data, WT1 or PRAME were considered overexpressed in a patient if the expression value was greater than the mean of the entire cohort. The percentage of patients overexpressing WT1 or PRAME was calculated for the entire cohort and for patients who did not have NPM1 insertion mutations or fusion.
Digital droplet PCR (ddPCR)
CBFB-MYH11 type A expression was determined for the ME-1 cell dilutions by ddPCR.
The established EAC assay for CBFB-MYH11 type A was adapted for use on the 
ArcherDx Myeloid FusionPlex library preparation and analysis
Anchored multiplex PCR-based enrichment RNA-sequencing libraries were generated using the ArcherDx Myeloid FusionPlex assay for Illumina (cat# AB0037, ArcherDx, Boulder, CO), per manufacturer's instructions. In short, 250ng of RNA from the ME-1 and 
Molecular analysis of CBFB-MYH11 isoform
To confirm the CBFB-MYH11 isoform present in the bone marrow of patient J ( 
